3Belani CP, Einzig A, Bonomi P, et al. Muhicenter phase II trial of doeelaxel and carboplatin in patients with stage Ⅲ B and IV non-small-cell-lung cancer[J]. Ann Oncol,2000,11 (6) :673 -678.
4Oka M, Fukuda M. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell-lung cancer[ J ]. Cancer Chemother pharmacol, 2001, 48 ( 6 ) : 446 - 450.
5Sirotnak FM. Studies with ZD1839 in preclinical models[J]. Semin Oncol, 2003,30 (Suppl 1):12 - 20.
6Ritter CA, Arteaga CL. The epidermal growth factor receptor - tyrosine kinase:A promising therapeutic target in solid tumors[J]. Semin Oncol,2003,30(Suppl 1) :3 - 11.
7Schiller JH. New directions for ZD1839 in the treatment of solid tumors[ J ]. Semin Oncol, 2003,30 (Suppl 1): 49 - 55.
8Lorusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease- related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors[J ]. Clin Cancer Res, 2003,9(6): 2040 - 2048.
